UCB FIRST LOOK: Additional two-year Bimzelx data in HS
UCB announced additional two-year follow-up data for Bimzelx in hidradenitis suppurativa (HS), showing significant improvements in disease severity and sustained disease control. The data underlines Bimzelx' strong performance compared to competitors, with expectations of becoming the standard of care in HS following recent FDA approval in November 2024. We reiterate our € 214 TP and Accumulate rating.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.